0001104659-24-060594.txt : 20240513 0001104659-24-060594.hdr.sgml : 20240513 20240513163243 ACCESSION NUMBER: 0001104659-24-060594 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240509 FILED AS OF DATE: 20240513 DATE AS OF CHANGE: 20240513 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brenner Martin CENTRAL INDEX KEY: 0001770235 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 24939634 MAIL ADDRESS: STREET 1: C/O PFENEX INC. STREET 2: 10790 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 4 1 tm2414241-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-05-09 0 0001420720 iBio, Inc. IBIO 0001770235 Brenner Martin C/O IBIO, INC., 8800 HSC PARKWAY BRYAN TX 77807 0 1 0 0 See Remarks 0 Stock Option (right to buy) 1.88 2024-05-09 4 A 0 147300 0 A 2034-05-09 Common Stock 147300 147300 D Stock Option (right to buy) 1.88 2024-05-09 4 A 0 110000 0 A 2034-05-09 Common Stock 110000 110000 D These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc. These options vest in equal amounts on a quarterly basis over a 36-month period commencing on the date of grant. Chief Executive Officer and Chief Scientific Officer /s/ Martin Brenner 2024-05-13